AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
Ludwig San Diego researchers show that one way to override the growth-promoting effects of the loss of tumor suppressor gene PTEN is to inhibit a separate tumor suppressor gene.
Ludwig Harvard researchers have discovered a metabolic weakness in triple-negative breast cancer (TNBC) cells that may be exploited to quell their resistance to chemotherapy.
Chi Van Dang will join Ludwig as Scientific Director on July 1, 2017. A hematological oncologist and renowned researcher, Dang joins Ludwig from the University of Pennsylvania’s Abramson Cancer Center, which he has directed since 2011.